Perron Institute for Neurological and Translational Science, University of Western Australia, Perth, Australia.
Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Australia.
Brain Behav. 2022 Feb;12(2):e2494. doi: 10.1002/brb3.2494. Epub 2022 Jan 27.
To determine whether serum neurofilament light chain (sNfL) levels are suppressed in patients with the clinically isolated syndrome (CIS) following narrowband ultraviolet B phototherapy (UVB-PT).
sNfL levels were measured using a sensitive single-molecule array assay at baseline and up to 12 months in 17 patients with CIS, 10 of whom received UVB-PT, and were compared with healthy control (HC) and early relapsing remitting multiple sclerosis (RRMS) group. sNfL levels were correlated with magnetic resonance imaging total lesion volume (LV) determined using icobrain version 4.4.1 and with clinical outcomes.
Baseline median sNfL levels were significantly higher in the CIS (20.6 pg/mL, interquartile range [IQR] 13.7-161.4) and RRMS groups (36.6 pg/ml [IQR] 16.2-212.2) than in HC (10.7 pg/ml [IQR] 4.9-21.5) (p = .012 and p = .0002, respectively), and were strongly correlated with T2 and T1 LV at 12 months (r = .800; p = .014 and r = .833; p = .008, respectively) in the CIS group. Analysis of changes in sNfL levels over time in the CIS group showed a significant cumulative suppressive effect of UVB-PT in the first 3 months (UVB-PT -10.6% vs non-UVB-PT +58.3%; p = .04) following which the levels in the two groups converged and continued to fall.
Our findings provide the basis for further studies to determine the utility of sNfL levels as a marker of neuro-axonal damage in CIS and early MS and for assessing the efficacy of new therapeutic interventions such as UVB-PT.
确定在接受窄带紫外线 B 光疗 (UVB-PT) 的临床孤立综合征 (CIS) 患者中，血清神经丝轻链 (sNfL) 水平是否受到抑制。
使用灵敏的单分子阵列测定法在基线和 17 名 CIS 患者的 12 个月内测量 sNfL 水平，其中 10 名患者接受了 UVB-PT，并与健康对照 (HC) 和早期复发缓解型多发性硬化症 (RRMS) 组进行比较。sNfL 水平与使用 icobrain 版本 4.4.1 确定的磁共振成像总病变体积 (LV) 以及临床结果相关。
CIS（20.6pg/ml，四分位距 [IQR] 13.7-161.4）和 RRMS 组（36.6pg/ml [IQR] 16.2-212.2）的基线中位数 sNfL 水平明显高于 HC（10.7pg/ml [IQR] 4.9-21.5）（p=0.012 和 p=0.0002），并且与 CIS 组 12 个月时的 T2 和 T1 LV 呈强烈相关性（r=0.800；p=0.014 和 r=0.833；p=0.008）。对 CIS 组 sNfL 水平随时间的变化进行分析，结果表明 UVB-PT 在治疗的前 3 个月具有显著的累积抑制作用（UVB-PT-10.6%vs 非 UVB-PT+58.3%；p=0.04），此后两组的水平趋于一致并继续下降。
我们的研究结果为进一步研究提供了依据，以确定 sNfL 水平作为 CIS 和早期 MS 中神经轴突损伤的标志物的效用，并评估 UVB-PT 等新治疗干预措施的疗效。
